bioAffinity Technologies (BIAFW) Common Equity (2021 - 2026)

bioAffinity Technologies has disclosed Common Equity across 6 years of filings, most recently posting $3.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 154.37% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 154.37% YoY), while the FY2025 annual figure was $7.3 million, up 179.69% from the prior year.
• Common Equity declined to $3.7 million in Q1 2026, from $7.3 million in the prior quarter.
• Over the last five years, Common Equity for BIAFW reached as high as $12.6 million in Q3 2022 and fell as low as -$16.8 million in Q2 2022.
• The 5-year median for Common Equity is $4.9 million (2023), against an average of $3.1 million.
• The widest YoY moves for Common Equity: up 185.23% in 2025, down 162.22% in 2025.
• A 5-year view of Common Equity shows it stood at $11.0 million in 2022, then slumped by 56.03% to $4.9 million in 2023, then slumped by 46.41% to $2.6 million in 2024, then soared by 179.69% to $7.3 million in 2025, then sank by 49.69% to $3.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.7 million, $7.3 million, and $8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.